NEW YORK (GenomeWeb News) – Strategic Diagnostics and the Fred Hutchinson Cancer Center said yesterday that they will collaborate to discover biomarkers for use in the early detection of a variety of cancers.
Under the collaboration, which will initially focus on pancreatic cancer, Newark, NJ-based SDI will provide approximately 1,000 of its cancer antigen antibodies to Paul Lampe, full member and associate program head of the Molecular Diagnostics Program at Seattle's Hutchinson Center.
The antibodies, which were designed using SDI’s proprietary Genomic Antibody Technology, will be printed by the Lampe laboratory onto microarray slides and tested against up to 200 characterized patient case samples and controls in a first discovery screening assay.
Upon completion, the Hutchinson Center and SDI plan to jointly publish the biomarker findings of the studies. SDI will have an option to license from the Hutchinson Center the commercial rights to any work developed during the collaboration.
"This initiative exemplifies the value of our suite of fully-integrated immuno-solution capabilities, which includes our proprietary Genomic Antibody Technology," SDI President and CEO Fran DiNuzzo said in a statement. "Moreover, it is aligned with our strategic direction as an emerging contributor to the biomarker discovery and development community."